East Brunswick, NJ, June 1, 2018. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Modafinil 100 and 200mg tablets. This launch adds to Avet’s robust portfolio of generic oral solid products. Modafinil is the AB rated generic equivalent to the wakefulness-promoting drug Provigil®*. It is indicated for the treatment of disorders such as narcolepsy, shift work sleep disorder and obstructive sleep apnea. According to IMS data for the twelve-months ended May 2018, the U.S. market for Modafinil tablets is approximately $112 million.